In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report.
The Cell and Gene Therapy Catapult (CGT Catapult) has today published the ‘National Cell and Gene Therapy Vision for the UK’, a document outlining recommendations for a national strategy for the adoption of cell and gene therapies.
The Cell and Gene Therapy Catapult and Deep Science Ventures have formed a partnership aimed at creating innovative approaches to address barriers in the Advanced Therapy Medicinal Products (ATMP) industry.
CGT Catapult adds six additional clean room spaces to its Stevenage manufacturing center, to aid companies readying themselves for clinical and commercial manufacture.
Brexit will not stifle interest in the UK’s cell and gene therapy space, says the CGT Catapult which has reported a tenfold growth in investment since 2012 to £400m ($520m).
